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Background: Nucleoporins mediate nucleocytoplasmic exchange of macromolecules and several have been
assigned active mitotic functions. Nucleoporins can participate in various mitotic functions like spindle assembly,
kinetochore organisation and chromosome segregation- important for genome integrity. Pathways to genome
integrity are frequently deregulated in cancer and many are regulated in part by microRNAs. Indeed, altered levels of
numerous microRNAs have frequently been associated with tumorigenesis. Here, we unveil a microRNA-mediated
regulation of the nucleoporin Nup214 and its downstream effect on genome integrity.
Methods: Databases/bioinformatic tools such as miRBase, Oncomine and RNAhybrid predicted Nup214 as a miR-133b
target. To validate this, we used luciferase reporter assays, Real-Time PCR and immuno-blotting. Flow cytometry and
immuno-blots of mitotic markers were used to analyse cell cycle pattern upon thymidine synchronization and miR-133b
treatment. Mitotic indices and chromosomal abnormalities were assessed by immuno-fluorescence for FITC-tagged
phospho-H3 as well as video-microscopy for GFP-tagged histone H4. Annexin V/propidium iodide staining, caspase3/
PARP cleavage and colony formation assays were done to investigate cell death upon either miR-133b transfection or
NUP214 knockdown by siRNA. UPCI:SCC084, HCT116, HeLa-H4-pEGFP and HEK293 (human oral squamous cell
carcinoma, colorectal, cervical carcinomas and embryonic kidney cell lines, respectively) were used. miR-133b and
NUP214 expressions were validated in cancer cell lines and tissues by Real-Time PCR.
Results: Examination of head and neck tumour tissues and cancer cell lines revealed that Nup214 and miR-133b
expressions are negatively correlated. In vitro, Nup214 was significantly downregulated by ectopic miR-133b. This
downregulation elevated mitotic indices and delayed degradation of mitotic marker proteins cyclinB1 and cyclinA
and dephosphorylation of H3. Moreover, this mitotic delay enhanced chromosomal abnormalities and apoptosis.
Conclusions: We have identified NUP214, a member of the massive nuclear pore complex, as a novel miR-133b
target. Thus, we have shown a hitherto unknown microRNA regulation of mitosis mediated by a member of the
nucleoporin family. Based on observations, we also raise some hypotheses regarding transport-dependent/independent
functions of Nup214 in this study. Our results hence attempt to explain why miR-133b is generally downregulated in
tumours and lay out the potential for Nup214 as a therapeutic target in the treatment of cancer.
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MicroRNAs (miRNA) are endogenous, non-coding RNAs
that direct gene repression by inhibiting the mRNA stabil-
ity or translation [1]. Evolutionarily conserved, they fre-
quently target 3′ untranslated regions (UTRs) of target
transcripts [2]. A variety of cellular events such as prolifer-
ation, differentiation and apoptosis are controlled by
miRNAs- thus implicating them in tumorigenesis [3,4].
Moreover, altered expression levels of miRNAs have been
associated with myriad kinds of cancers [4]. However, elu-
cidation of molecular pathogenic pathways involving these
miRNAs has not kept pace with the fast-increasing num-
ber of association studies between altered miRNA expres-
sions and different types of cancers.
Meanwhile, a vast, complex network of signalling path-
ways mediate tumour progression and all such signals
have to enter the nucleus through the only gateway- the
nuclear pore complex (NPC). The NPCs regulate the
nucleocytoplasmic trafficking of macromolecules and are
massive protein complexes within the cell, composed of
multiple copies of about 30 different nucleoporins (Nups)
[5,6]. Cell division demands exquisite control over the ar-
rangement and location of events and failure to observe
this control has dire consequences, including chromo-
some mis-segregation and aneuploidy [7]. The activation
or inactivation of a series of mitotic regulators determines
the timing, but the completion of one event [for example,
nuclear envelope breakdown (NEBD)] might also provide
a signal for the beginning of the next, maintaining a
chronological sequence through mitosis. Unveiling of sur-
prising links between the nuclear transport machinery,
kinetochore and the spindle assembly checkpoint (SAC)
besides canonical mitotic proteins [8] support this idea
[9,10]. Certain proteins that localize to the NPC in inter-
phase can relocalize to the kinetochores during mitosis,
wherein they are required for the alignment of chromo-
somes to the metaphase plate. The sequestration of kin-
etochore proteins at the NPC might therefore ensure that
the kinetochores cannot function until NEBD has been
completed [11]. For instance, the checkpoint proteins
Mad1, Mad2 and Mps1 are all associated with the NPCs
in vertebrate cells [12]. Remarkably, this ‘dual citizenship’
is reciprocal: Nups also localize to both nuclear pores and
kinetochores, and seem to perform distinct functions in
each location [11]. Hence, the mayhem that can occur
from the disruption of even a single Nup function is
fathomable. Moreover, the dynamics of NPCs are tightly
regulated during the cell cycle [13]. Although it was as-
sumed that Nups were just structural components of the
NPC, this view was transformed by the surprising discov-
ery that Nup107 and Nup133 localize to the spindle poles
and to the kinetochores during mitosis [14]. In this con-
text, several Nups such as Nup153, Nup 107–160 com-
plex, Tpr, Rae1 and Nup88 have been implicated inmitotic processes such as chromosome condensation,
sister-chromatid cohesion, kinetochore assembly and spin-
dle formation. Naturally, altered cellular levels of Nups
can thus contribute to chromosomal instability (CIN), an-
euploidy and tumorigenesis [15]. In this regard, it is well-
documented that CIN and aneuploidy are hallmarks of
many different malignancies [16,17]. Furthermore, deregu-
lation of the cell cycle in general and mitosis in particular
is known to be frequently causal to CIN [18,19].
Our earlier data predicted a large number of mitotic
targets of miRNAs deregulated in head and neck squa-
mous cell carcinoma (HNSCC) [20]. Of these, NUP214
was observed to be a potential target of hsa-miR-133b, a
downregulated miRNA in HNSCC. The human proto-
oncogene NUP214 is reported to have a dual role in nu-
clear protein import and mRNA export. The fact that
mice embryos homozygous for the disrupted NUP214
allele die in utero mirrors the essentiality of Nup214 for
cell survival [21]. Moreover, Nup214 localizes to both
the cytoplasmic and nucleoplasmic sides of the NPC in
over-expressing cells [22]. Additionally, it is also re-
ported to be recruited to the spindles during mitosis
[23,24]. However, the exact function of Nup214 in mi-
tosis remains elusive till date. Moreover, to the best of
our knowledge, the role of miRNAs in the regulation of
Nups has not been elucidated yet. Given the fact that
both Nups and miRNAs are crucial to genome integrity,
here we aim to elucidate how the regulation of one (Nup)
by the other (miRNA) modulates this very genome integ-
rity as well as its possible implications in tumorigenesis.
In the current study, we present NUP214 as a novel
target of miR-133b. We also show that downregulation
of Nup214 by miR-133b perturbs the normal mitotic
progression. This perturbation subsequently gives rise to
chromosomal abnormalities and leads to cell death by
apoptosis. Through our study, we also raise some inter-
esting questions about the possible locations and func-
tions of Nup214 during mitosis.
Results
In silico analysis predicts miR-133b binding site on
NUP214 3′UTR
Through an in silico prediction for a number of miRNAs
by miRBase, we had shown that NUP214 is a putative tar-
get of miR-133b [20]. Briefly, expression status of potential
miR-133b target genes were determined by Oncomine
database analysis and those which were reported to be up-
regulated in HNSCC (inverse to miR-133b underexpres-
sion) were selected. NUP214 was found to feature in this
list of targets. Indeed, RNAhybrid analysis revealed that
the 3′UTR of NUP214 has a miR-133b recognition site at
position 9 to 36 (Additional file 1A and B). It was also
found that the NUP214 expression levels are elevated in a
number of cancers (Additional files 1C and 2).
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correlated in cancer cell lines and primary HNSCC tissue
samples
miR-133b has been reported to be downregulated in sev-
eral SCC cell lines [25]. Preliminarily, we began with test-
ing and reconfirming that miR-133b expression is indeed
low in two SCC cell lines UPCI:SCC084 and SCC25 than
in normal oral epithelial cells (Figure 1a). Conversely, we
found that the NUP214 transcript levels are also higher in
the same cell lines (Figure 1b). Moreover, this inverseFigure 1 miR-133b targets NUP214 and their expressions are inversel
cell lines compared to control oral epithelial cells. (b) Corresponding levels
oral epithelial cells. (c) Reciprocal relation of miR-133b and NUP214 express
the data plotted as shown. ‘n’ represents number of tumour samples; aster
samples with P-value < 0.0005. (d) NUP214 is reduced at the mRNA level in
transfected with 0, 0.25, 0.5, 1 and 2 μg of pSB-miR-133b. (e) Representative p
expression. UPCI:SCC084 cells were transiently transfected with 0, 0.25, 0.5, 1 a
blot with antibodies against Nup214 and β-actin. For (a) and (c), total RNA fro
HNSCC tumour and normal tissues were reverse transcribed using miR-133b-s
expression values were normalized to those of miR-17-5p or (for cell lines) or
RT-PCR using NUP214-specific primers. Relative expression values were norma
(b) and (d), data represent three independent experiments and are shown as
three independent experiments. For all figures, asterisk denotes significant cha
with p value <0.05; NS – not significant.expression pattern was observed in other cancer cell lines
like HCT116 as well, with the exception of only SW480
(Figure 1a and b). We thus selected the UPCI:SCC084 and
HCT116 cell lines to study the possible role of miR-133b
in NUP214 regulation.
Similarly, the pooled data from ten HNSCC tissue sam-
ples demonstrated that indeed, miR-133b and Nup214 ex-
pressions are inversely related in these samples (Figure 1c).
The relative expression table reveals a median ~300 fold
decrease in miR-133b and ~7 fold increase in Nup214y related. (a) Expression of endogenous miR-133b in different cancer
of endogenous NUP214 in the same cell lines compared to control
ions in HNSCC tissues. Relative expression values were calculated and
isk denotes significant difference of expression in tumour versus normal
presence of ectopic miR-133b. UPCI:SCC084 cells were transiently
icture showing Nup214 protein level decreases upon ectopic miR-133b
nd 2 μg of pSB-miR-133b. Cell lysates were prepared followed by Western
m oral swab (control), UPCI:SCC084, SCC25, SW480, HCT116 cells and
pecific stem-loop primers. cDNAs were subjected to RT-PCR. Relative
U6 snRNA (for tissues). For (b), (c), and (d), cDNA was subjected to
lized to those of GAPDH (for cell lines) or 18 s rRNA (for tissues). For (a),
average ± standard deviation (S.D). For (e) images are representative of
nge when compared to either control or miR-133b-treated condition
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to support to an extent, our in vitro observations. Patho-
logical details of these samples can be found in Additional
file 4.
miR-133b binds to the NUP214 3′UTR and negatively
regulates its expression
In order to establish NUP214 as a bona fide target of miR-
133b, we transfected UPCI:SCC084 cells with different
doses of miR-133b expression-plasmid and measured
NUP214 both at the mRNA and protein levels. We ob-
served that the NUP214 transcript levels decreased in
consonance with the increasing doses of the miRNA indi-
cating that miR-133b regulates NUP214 at the post-
transcriptional level (Figure 1d and Additional file 5A).
Similarly, Nup214 also declined at the protein level upon
ectopic miR-133b expression (Figure 1e and Additional
file 5B). Moreover, the observation that the levels of an-
other unrelated Nup, Nup98 that does not carry a rec-
ognition site for miR-133b, remained unaffected by
miR-133b confirmed the specificity of this interaction
(Additional file 5C). Additionally, the mitotic gene BUB1
(does not have a recognition-site for miR-133b) also
remained unchanged upon miR-133b transfection which
further strengthened this specificity (Additional file 5D-F).
On the other hand, the NUP214 levels also remained un-
altered in presence of another unrelated miRNA, miR-
125b, which does not have a binding site on NUP214
(Additional file 5G-I).
Next, we co-transfected UPCI:SCC084 cells with either
pSB-NUP214/3′UTRLuc (Figure 2a) or pSB-NUP214/3′
UTRMutLuc (Figure 2c) with increasing doses of miR-
133b and measured the relative luciferase activity. In ac-
cord, a dose-dependent decrease in luciferase activity
was observed for the 3′UTR containing the wild type
miR-133b recognition site (Figure 2b). Contrastingly, no
significant change in luciferase activity was observed for
the mutant NUP214 3′UTR (Figure 2d). To further for-
tify these findings, we also co-transfected UPCI:SCC084
cells with an anti-sense inhibitor against miR-133b along
with the miRNA and pSB-NUP214/3′UTRLuc. As ex-
pected, miR-133b was not available to bind to its target
site on the NUP214 3′UTR and for this reason, was un-
able to restrain the luciferase activity (Figure 2e). Overall,
these results prove that miR-133b binds to the NUP214 3′
UTR and specifically downregulates its expression.
Nup214 repression by ectopic miR-133b retards mitotic
progression
A number of Nups are known to be involved in different
mitotic processes [15]. In view of the fact that we were
interested in identifying miRNA-mediated regulatory
pathways in mitosis, and also because the regulation of
mitotic proteins at the import/export level is crucial, weinitially investigated whether Nup214 repression by miR-
133b could affect the cell cycle/mitotic progression. To-
ward this, we used three different strategies to examine
the effect of ectopic miR-133b on the cell cycle progres-
sion of UPCI:SCC084 cells synchronized by thymidine
treatment and released from G1 block. First, FACS ana-
lysis of vector-transfected cells revealed that their peak
accumulation at the G2/M phase (48.10%) occurred at
6 h post-release. By 10 h from release, percentage of
cells in G2/M reduced to 24.33% (Figure 3a and b, upper
panels). In comparison, 48.44% of cells over-producing
miR-133b were in G2/M at 8 h from release, and
remained insignificantly changed (39.7%) even at 10 h
post-release (Figure 3a and b, lower panels).
Secondly, we monitored the mitotic progression by
examining the cyclic levels of cyclinB1 and phospho his-
tone H3 (p-H3)- marker proteins for mitosis, in both
UPCI:SCC084 and HCT116 cells. For vector-transfected
UPCI:SCC084 cells, cyclinB1 peaked at 8–10 h post-
release, after which it declined, manifesting a mitotic exit
(Figure 3c, left panel and d). In contrast, upon ectopic
miR-133b expression cyclinB1 did not degrade even at
12 h post-release implying that the cells were yet to exit
from mitosis (Figure 3c, middle panel and d). Further,
specificity of this mitotic regulation mediated by miR-
133b was proved by the observation that rapid degrad-
ation of cyclinB1 could be reconstituted by ectopic
Nup214 expression even in the presence of miR-133b
(Figure 3c, right panel and d). Moreover, the observation
made for cyclinB1 was replicated by the phosphorylation-
dephosphorylation pattern of H3 (Figure 3c and f). Simi-
larly, cyclinB1 and p-H3 were found to be stabilized by
miR-133b and their degradation and dephosphorylation,
respectively, were rescued by Nup214 in HCT116 cells as
well (Figure 3g, h and i). These results together demon-
strate that excess miR-133b arrests the cells in mitosis by
suppressing the Nup214 levels. At this point, it is worth
mentioning that owing to the absence of the 3′UTR rec-
ognition site for miR-133b in the Nup214 expression-
plasmid, Nup214 is able restore the original phenotype
even in presence of the miRNA.
Third, we scored the mitotic indices (MI) of HCT116
cells treated with miR-133b based on the p-H3-FITC
positive signal. The data supported the above findings in
that the MI was higher for cells treated with miR-133b
(49%) as compared to vector-treated cells (7.5%) at the
10 h time point (Figure 4a and b). As before, co-
expression of Nup214 was able to retrieve the MI to a
significant extent (18.6%) (Figure 4a and b). We also
supplemented our results with time-lapse monitoring
of live Hela-H4-pEGFP cells transfected with miR-133b.
The results illustrated that in cells treated with miR-
133b, mitosis remained blocked (Figure 4c, middle row
and Additional file 6B) even as vector-treated (Figure 4c,
Figure 2 Binding of miR-133b to NUP214 is specific. (a) and (c) Cartoons showing the two NUP214 3′UTR constructs used for luciferase assay.
(a) represents wild type NUP214 3′UTR downstream of luciferase gene while (c) shows NUP214 3′UTR where the target site for miR-133b is
mutated. (b) miR-133b decreases luciferase activity in presence of NUP214 3′UTR. UPCI:SCC084 cells were transiently co-transfected with 0.5 μg
pSB-NUP214/3′UTRLuc and 0, 0.25, 0.5, 1 or 2 μg of pSB-miR-133b. Protein lysates were prepared for luciferase assay. (d) Mutant NUP214 3′UTR
prevents inhibition by miR-133b. UPCI:SCC084 cells were co-transfected with either 0.5 μg pSB-NUP214/3′UTRLuc, or pSB-NUP214/3′UTRMutLuc
along-with 0 or 1 μg pSB-miR-133b. Protein lysates were prepared for luciferase assay. (e) Blocking miR-133b prevents NUP214 repression. UPCI:
SCC084 cells were transiently transfected with only pSB-NUP214/3′UTRLuc (0.5 μg), or with pSB-NUP214/3′UTRLuc (0.5 μg) and pSB-miR-133b
(1 μg), or with pSB-NUP214/3′UTRLuc (0.5 μg), pSB-miR-133b (1 μg) and anti-miR-133b (20 nM). Protein lysates were prepared for luciferase assay.
For (b), (d) and (e), data represent three independent experiments and are shown as average ± S.D.
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cells (Figure 4c, bottom row and Additional file 6C) pro-
ceeded to anaphase and further, within 1 h of monitoring.
The above results fostered the idea that some mitotic
factor essential to cell cycle progression may be unable
to enter the nucleus in presence of ectopic miR-133b
and consequent absence of or low Nup214. To find out
whether this possible mitotic cargo of Nup214 functions
in the early or late mitotic phase, we followed the levelsof cyclinA (whose degradation is an early mitotic marker)
in synchronized UPCI:SCC084 as well as HCT116 cells
transfected with miR-133b. Indeed, we found that while
for vector-transfected UPCI:SCC084 cells cyclinA levels
peaked at 4 h post-release (Figure 3c, left panel and f), ec-
topic miR-133b seemed to bring about the stabilization of
the protein till around the 10 h time-point (Figure 3c,
middle panel and f). Moreover, similar to the observations
with cyclinB1, here too, ectopic expression of Nup214
Figure 3 miR-133b perturbs mitotic timing by downregulating Nup214. (a) and (b) miR-133b halts cells at G2/M phase. UPCI:SCC084 cells
were transiently transfected with 1 μg pSB-miR-133b or empty vector, synchronized and harvested at 0, 4, 6, 8 and 10 h from second thymidine
release. DNA content was analysed by flow cytometry. (a) shows representative images while (b) shows the percentage of cells in each phase at
each time-point. (c) and (g) Representative pictures showing miR-133b delays cyclinB1, cyclinA degradation and H3 dephosphorylation while
Nup214 rescues the normal pattern even in presence of miR-133b. UPCI:SCC084 (c) and HCT116 (g) cells were transiently transfected with empty
vector (1 μg), pSB-miR-133b (1 μg), or pSB-miR-133b (1 μg) and pCMV-Myc-CAN/Nup214 (1 μg), and synchronized. Cell lysates were prepared at
0, 4, 6, 8, 10 and 12 h from second thymidine release followed by Western blot with antibodies against cyclinB1, cyclinA, p-H3, Nup214 and
β-actin. (d), (e), (f), (h), (i) and (j) Densitometric values of bands by ImageJ are plotted: cyclinB1 (d, h) and cyclinA (f, j) were normalized to
β-actin. P-H3 (e, i) was normalized to total H3. All three proteins were further normalised to the respective protein expressions at 0 h in empty
vector-treated cells. For (a), (c) and (g), images are representative of three different experiments while for (d), (e), (f), (h), (i) and (j), data represent three
independent experiments and shown as average ± S.D. Black arrow in (g) represents a non-specific band.
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pattern of cyclinA (Figure 3c, right panel and f). Addition-
ally, this pattern of cyclinA degradation, stabilization by
miR-133b and rescue by Nup214 was reproduced in
HCT116 cells once again (Figure 3g and j). Hence, these
results further bolstered our hypothesis that miR-133b ar-
rests cells in early mitosis probably by disturbing the im-
port/export of some crucial mitotic factor through the
downregulation of Nup214.
miR-133b-induced disturbance in mitotic progression
causes chromosomal abnormalities
We next hypothesised that miR-133b might give birth to
chromosomal abnormalities as a consequence of the mi-
totic arrest. Upon addressing this, synchronized HCT116
cells revealed that chromosomal abnormalities were in-
deed strikingly conspicuous in miR-133b overproducing
cells at the 12 h and 14 h time points (from release) ascompared to vector-transfected cells (Figure 5a, 1st and
2nd rows and b). P-H3 immuno-staining in these abnormal
chromosomes gave further credence that it is the miR-
133b-mediated mitotic perturbation that induces chromo-
somal aberrations. Besides, ectopic expression of Nup214
along with miR-133b was also able to revoke the rise in
chromosomal aberrations that was observed in presence
of miR-133b alone, thus establishing the specificity of our
results (Figure 5a, 3rd row and b). Collectively, these data
confirm that miR-133b induces chromosomal abnormal-
ities in a Nup214-specific manner.
miR-133b-mediated mitotic defects leads to cell death via
apoptosis
Finally, we examined the phenotypic consequence of the
miR-133b-mediated Nup214 downregulation and the
following mitotic disturbances by studying its effect on
the clonogenicity of UPCI:SCC084 cells. According to
Figure 4 miR-133b modulates mitotic timing. (a) and (b) HCT116 cells were transiently transfected with empty vector (1 μg), pSB-miR-133b
(1 μg), or pSB-miR-133b (1 μg) and pCMV-Myc-CAN/Nup214 (1 μg) and synchronized. At 4, 6, 8 and 10 h from second thymidine release, cells
were fixed, stained with DAPI and visualized under a fluorescence microscope. Representative images are shown (a). Only brightly-stained (FITC)
cells were considered for MI evaluation. Scale bar represents 10 μm. Images represent 40× magnification. MI were calculated and plotted as
shown (b); represents three independent experiments and shown as average ± S.D. (c) HeLa-H4-pEGFP stable cells were transiently transfected
with empty vector (1 μg), pSB-miR-133b (1 μg), or pSB-miR-133b (1 μg) and pCMV-Myc-CAN/Nup214 (1 μg) and synchronized. Medium was
replaced with phenol red-free medium and visualized under time lapse fluorescence microscope. ‘0.00’ time-point is that time (8 h post-release)
when chromosomes for each of the three treated condition were found to be aligned at the metaphase plate. Representative frozen images are
shown and time stamps indicated. Scale bar represents 5 μm. Images represent 63× magnification.
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cells gave rise to significantly less number of colonies
than those formed by vector-transfected cells (Figure 6a
and b). This indicated that miR-133b might reduce cell
viability, probably in part, due to the enhancement of
chromosomal abnormalities following the mitotic pro-
gression defects shown before.
For a clearer insight into this observation, however, it
was interesting to probe whether the reduction in colony
number was due to apoptotic cell death and if so,
whether the viability could be retrieved upon ectopic
Nup214 expression. Toward this, we performed apoptosisassays in miR-133b-transfected UPCI:SCC084 cells in two
different ways. Firstly, time kinetic FACS analysis of
annexinV/propidium iodide (PI) stained cells revealed that
cells indeed underwent programmed cell death 72 h after
miR-133b treatment (39.15%) as compared to vector-
treated cells at the same time point (3.9%) (Figure 6c
and d). Secondly, evaluation of caspase3 cleavage using
flow cytometry was carried out in the above cells. Our re-
sults indicate that there is an elevation in caspase3 activa-
tion about 72 h post miR-133b transfection in comparison
to vector-treated cells at the same time point (Figure 6e).
Interestingly, Nup214 co-expression was able to prevent
Figure 5 Excess miR-133b enhances chromosomal abnormalities. (a) and (b) HCT116 cells were transiently transfected with empty vector
(1 μg), pSB-miR-133b (1 μg), or pSB-miR-133b (1 μg) and pCMV-Myc-CAN/Nup214 (1 μg) and synchronized. Immuno-staining was done with
antibody against p-H3 and nuclei were stained with DAPI at 12 and 14 h from second thymidine release. Cells were visualized under a fluorescence
microscope. (a) Representative images are shown and the defects indicated by white arrows. Scale bar represents 10 μm. Images represent 60×
magnification. (b) Percentages of mitotic abnormalities were calculated and plotted as shown. Data represents three independent experiments and
shown as average ± S.D.
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ments (Figure 6c-e). A strong corroboration for these
results was achieved when on one hand, specific knock-
down of Nup214 in UPCI:SCC084 cells with a pool of
siRNAs (Figure 7a and b) gave the same phenotype for
cell death as was seen with miR-133b (Figure 7c-f). On
the other hand, treatment of non-tumoral HEK293 cells
with the same dose of miR-133b demonstrated no sig-
nificant deviations in either colony number (Additional
file 7A and B) or in percentage of apoptotic cells (Additional
file 7C and D) when compared to control vector-treated
cells. Collectively, these results confirm our view that cells
are rendered non-viable by miR-133b in a Nup214-
specific manner.Discussion
We have validated here that the human miR-133b can
specifically repress the nucleoporin proto-oncogene
NUP214. miR-133b remains downregulated in head and
neck, bladder, colorectal, gastric, lung and prostate can-
cers while it is upregulated in cervical cancer [26]. This
miRNA is also reported to be tumour suppressive in
esophageal squamous cell carcinoma [27]. Furthermore,
miR-133b has been shown to target anti-apoptotic genes
to mediate death-receptor-induced apoptosis [28]. The
present study further illustrates that the miR-133b-
mediated Nup214 downregulation delays cells in the
early mitotic phase and thus leads to aberrant chromo-
some segregation and cell death. Importantly, from our
Figure 6 miR-133b-mediated mitotic delay leads to cell death. (a) and (b) Ectopic miR-133b affects clonogenicity of cells. UPCI:SCC084 cells were
seeded at a density of 103 and transiently transfected with 0, 0.25, 0.5, 1 and 2 μg pSB-miR-133b. Colonies were stained with methylene blue after a week.
(a) Representative images are shown. (b) Colonies were counted from (a) and plotted as shown. (c) and (d) Excess miR-133b induces apoptosis. 105
UPCI:SCC084 cells were transiently transfected with empty vector (1 μg), pSB-miR-133b (1 μg), or pSB-miR-133b (1 μg) and pCMV-Myc-CAN/Nup214
(1 μg). At 0, 24, 48 and 72 h post-transfection, cells were subjected to annexin V-FITC/PI staining followed by flow cytometry analysis. (e) Ectopic
miR-133b elevates cleaved caspase3 levels. 105 UPCI:SCC084 cells were transiently transfected with empty vector (1 μg), pSB-miR-133b (1 μg), or pSB-miR-
133b (1 μg) and pCMV-Myc-CAN/Nup214 (1 μg). Cells were fixed, permeabilized and stained with control antibodies or cleaved caspase3 antibody at 0
and 72 h post-transfection followed by flow cytometric analysis. Colour codes of histograms and mean FITC values are indicated. For (b)-(d), data
represent three independent experiments and shown as average ± S.D. For (a) and (e), images are representative of three independent experiments.
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Figure 7 NUP214 knockdown by siRNAs attests miR-133b-induced phenotypes. (a) Representative picture showing Nup214 knockdown by
specific siRNAs. UPCI:SCC084 cells were transiently transfected with scrambled siRNA (80 nM), Nup214-specific siRNAs (80 nM), or Nup214-specific
siRNAs (80 nM) and pCMV-Myc-CAN/Nup214 (1 μg). Cell lysates were prepared followed by Western blot with antibodies against Nup214 and
β-actin. (b) Densitometric values of bands were normalized to those of β-actin by ImageJ and plotted. For (a) and (b), data represent three
independent experiments and shown as average ± S.D. (c) Nup214 knockdown represses colony forming potential of cells. UPCI:SCC084 cells were
seeded at a density of 103 and transiently transfected with scrambled siRNA (80 nM), Nup214-specific siRNAs (80 nM), or Nup214-specific siRNAs
(80 nM) and pCMV-Myc-CAN/Nup214 (1 μg). Colonies were stained with methylene blue after a week, counted and plotted as shown. (d) and
(e) Nup214 knockdown induces apoptosis. 105 UPCI:SCC084 cells were transiently transfected with scrambled siRNA (80 nM), Nup214-specific
siRNAs (80 nM), or Nup214-specific siRNAs (80 nM) and pCMV-Myc-CAN/Nup214 (1 μg). At 0 and 72 h post-transfection, cells were subjected to
annexin V-FITC/PI staining followed by flow cytometry analysis. Representative images are shown (d) and data plotted (e). (f) and (g) Nup214
knockdown elevates cleaved PARP levels. 105 UPCI:SCC084 cells were transiently transfected with scrambled siRNA (80 nM), Nup214-specific
siRNAs (80 nM), or Nup214-specific siRNAs (80 nM) and pCMV-Myc-CAN/Nup214 (1 μg). Cells were fixed, permeabilized and stained with control
antibodies or cleaved PARP antibody at 0 and 72 h post-transfection followed by flow cytometric analysis. Color codes of histograms are indicated
in representative images (f). Data was plotted as shown (g).
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import of one or more mitotic proteins (that is/are cell
cycle regulated) may be dependent on the levels of
Nup214 and hence, on the levels of miR-133b. Our study
highlights this possibility through a hitherto unknown
miRNA-regulated association of NUP214 with proper
mitotic progression.
It was previously reported that NUP214-depleted em-
bryo cells arrested in the G2 phase of the cell cycle [21]
while over-expressing cells arrested in G0 [22]. In our at-
tempt to uncover the downstream functional effects of
Nup214 downregulation by miR-133b, we also observed
a similar G2-M arrest in cells overproducing miR-133b
by flow cytometric analysis. The accumulation of cyclinA
in miR-133b treated synchronised cells was also able to
prove an early mitotic arrest. Furthermore, co-transfection
with Nup214 expression-plasmid was able to rescue the
degradation of both cyclinA and cyclinB1, dephosphoryla-
tion of p-H3 and the MI thus ascertaining the specificity
of this interaction. Moreover, the accumulation of cyclinB1
and p-H3 as well as increased MI endorsed the involve-
ment of one or more SAC proteins in this pathway.
Notably, because Nup214 lacks its 3′UTR in the
expression-vector, co-expression with miR-133b did not
alter Nup214’s ability to change the cellular phenotype.
This also indicates that other known targets of miR-133b
(like CXCR4 [29]) might not play any role in the NUP214-
mediated phenotype observed here. To the best of our
knowledge, Mad1 is the only SAC protein with known in-
teractions with different Nups across species other than
humans [30,31]. Nup88 and hCRM1 also have been previ-
ously identified as Nup214 interacting proteins [32]. Inter-
estingly a study of substrate transport through the NPC
upon NUP214 depletion revealed that the import of nu-
clear localization sequence (NLS)-containing proteins into
the nucleus was impaired [21]. However, in the absence of
concrete evidence for known associations of Nup214 with
any of the SAC proteins, for the time being we need to
leave it to experimental investigations for further elucida-
tion and explanation of our observations.
To be able to direct the mitotic perturbations to logical
explanations, it is incumbent on us to question the sub-
cellular localization and distinct functions of Nup214 at
mitosis. As mentioned in the Background section, Nup214
exhibits dual citizenship – being relocated from the nu-
clear pores at interphase to the spindles at mitosis. Not
much is known about this, however, in a study by Lussi
et al. [30], it has been shown that another member of the
Nup family, Nup153, can associate with Mad1 (a mitotic
protein). However, this role of Nup153 in mitosis was
found to be independent of its role in nucleocytoplasmic
transport. Because the localization of Nup214 at the spin-
dles during mitosis is as yet unexplained, we suggest a
similar situation wherein there may arise two possibilitiesat the initiation of mitosis: (1) the early mitotic arrest
might occur due to defective nuclear transport of some
protein/factor (discussed in the Results section) as a result
of Nup214 downregulation or (2) Nup214 downregulation
may cause mitotic arrest as a result of some altered
transport-independent event, for example, defective NEBD,
etc. (we mention NEBD because destruction of cyclinA is
known to start minutes after NEBD takes place [33]). Ac-
cording to our observations, the former seems to be more
plausible, stemming from the fact that cyclinA, cyclinB1
and p-H3 are stabilized upon Nup214 repression by miR-
133b. Nevertheless, the latter possibility also demands to
be probed by valid experiments.
An earlier report has shown that abolishment of
Nup214 from the spindles during mitosis results in
chromosome separation defects and aneuploidy, multi-
nucleate structures being the most dramatic [23]. In this
context, altered levels of another Nup, Nup153, has also
been implicated in the formation of multipolarization
and multilobulation of cells [30]. Similarly, our study
too, has shown chromosome defects upon Nup214
downregulation by miR-133b- particularly some which
appear like “flower cells” with greatly lobulated nuclei
(Figure 5a, 2nd row, 12 h time-point) as described by the
same authors [30]. miR-133b is reported in death-
receptor-induced apoptosis in HeLa cells and ex vivo
models of pancreatic cancer [28]. We too, observed ec-
topic miR-133b as well as Nup214 siRNA-mediated in-
duction of apoptotic cell death in UPCI:SCC084 cells.
Importantly, incidence of both chromosomal defects as
well as apoptosis was greatly reduced upon co-expression
of Nup214 along with miR-133b or the siRNA. Hence, we
speculate that the late mitotic exit leads to erroneous
chromosome segregation and abnormal nuclear structures
further leading to cell death, the phenomena being specific
to Nup214 in our study.
While the functions of NPCs in transport are well
established, coupling of the nuclear transport machinery
to processes that control chromosome segregation dur-
ing mitosis, including the SAC, is still an emerging area
of investigation. Our study contributes by involving
miRNA-mediated regulation in this process. These find-
ings might also help to understand the molecular mech-
anisms that contribute towards the high degree of CIN
associated with various cancers. In fact, given that miR-
133b is downregulated in HNSCC (and many other
cancers), our study has significant therapeutic implications-
(1) miR-133b mimics could potentially be used to alleviate
the oncogenic effects of endogenous Nup214 that lead to
malignancies, (2) molecules other than miRNA mimics
such as small molecules, nanoparticles or other silencing
RNAs could also be used against Nup214. More import-
antly, the preliminary observation that ectopic miR-133b
does not alter the fate of non-tumoral cells also makes it a
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observations have been validated in cell lines other than
UPCI:SCC084 (like HCT116 and HeLa) underscores a
broader functionality of these mechanisms in cancers. It
should be mentioned though that in colorectal cancer,
miR-133b has been shown to block cell proliferation by
directly targeting the c-MET protein [34]. However, here
we have defined Nup214 as a novel direct target of the
miRNA and extended our study to more than one cell
system.
Conclusions
In summary, (1) the nucleoporin gene NUP214 is a
novel target of miR-133b, (2) Nup214 downregulation
brings about early mitotic delay and (3) this delay gives
rise to chromosomal segregational defects and eventual
cell death. All these cellular effects of miR-133b appear
to be Nup214-specific. However, it is crucial to bear in
mind that miR-133b has other known and unknown tar-
gets across the cell cycle whereas NUP214 regulation
could also be controlled by hitherto un-validated miR-
NAs. Hence, a systemic study of miRNAs involved in
the regulation of Nup214 and its interacting partners is
warranted to fully understand the impact of miRNAs on
the development and progression of cancer. An in-depth
study of Nup214 localization and its precise functions at
its individual sites is also crucial to further our under-
standing of this phenomenon.
Methods
Cell culture, synchronization, drug treatment and
transfection
HCT116, SCC25, SW480 and HEK293 cell lines were
purchased from American Type Culture Collection
(Manassas, VA, USA) and HepG2 cell line was gifted by
Dr. Samit Adhya (Indian Institute of Chemical Biology,
India). Human oral cancer cell line UPCI:SCC084 was a
kind gift from Dr. Susanne M. Gollin (University of
Pittsburgh, USA). HeLa-H4-pEGFP stable cell line was
developed as reported previously [35]. All cell lines were
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM;
Invitrogen, Carlsbad, CA, USA) supplemented with 10%
fetal calf serum and antibiotics (1% Pen Strep Glutamine
and 0.006% Gentamicin, Invitrogen) at 37°C in a 5% CO2
incubator. For synchronization, cells were treated with
thymidine (2.5 mM; USB, Cleveland, USA) for 16 h
followed by an 8 h release. A second thymidine treatment
was given for another 22 h. Cells were released in thymi-
dine free complete medium and harvested at various time-
points following this double thymidine block. Transient
transfections were done with various plasmids, miRNA
inhibitors and siRNAs in different cell lines using Lipofec-
tamine 2000 reagent (Invitrogen) according to the manu-
facturer’s protocol. All transient transfections wereperformed for 48 h, except in case of synchronization ex-
periments. Transfection of synchronized cells was done
6 h before first thymidine addition. For induction of apop-
tosis by etoposide (Sigma) and camptothecin (Sigma), cells
were treated with the drug (20 μg/ml for 72 h and 3 μM
for 24 h, respectively) for the time-periods mentioned.
Plasmids, miRNA inhibitors and siRNAs
The cloning of pSB-miR-133b (human precursor miR-
133b; chromosome 6: 52011721–52015839, + strand) is
described by Bhattacharjya et al. [20]. The NUP214 3′
UTR (NM_005085.2, +6355 to +6475) was amplified
from human genomic DNA with the primers listed in
Additional file 8. This region was cloned into the linear-
ized pMIR-REPORT vector (Applied Biosystems, Foster
City, USA) downstream of the luciferase gene using the
MluI and HindIII restriction sites (New England Biolabs,
Beverly, MA). It is referred to as pSB-NUP214/3′UTRLuc
in the text. The mutant version of this clone was con-
structed using the primers listed in Additional file 8 and
Quikchange XL site-directed mutagenesis kit (Stratagene,
La Jolla, CA, USA) according to the manufacturer’s proto-
col. It is referred to as pSB-NUP214/3′UTRMutLuc in the
text. Full length Myc-tagged Nup214 expression-plasmid
pCMV-Myc-CAN/Nup214 was a kind gift from Dr.
Toshimi Michigami (Osaka Medical Center for Maternal
and Child Health, Japan). Anti miR-133b (Ambion, Austin,
TX, USA) was used at a final concentration of 20 nM. siR-
NAs directed against Nup214 (Santa Cruz Biotechnology)
as well as scrambled control (Ambion) were used at a final
concentration of 80 nM.
Quantitative Real-Time PCR
Total RNA from different cell lines, oral swab and tissue
specimens was isolated using TRIZOL (Invitrogen) ac-
cording to the manufacturer’s protocol. 5 μg isolated
RNA was treated with DNase (Promega, Madison, USA)
and 1 μg of this DNase treated RNA was used for cDNA
preparation using random hexamer (Invitrogen) and
MMLV-RT (Promega). For miRNAs, 200 ng isolated
RNA was used for cDNA preparation in a master mix
containing stem-loop primers specific for the desired
miRNAs (Sigma) as given in Additional file 9, dNTPs
(Invitrogen) and MMLV-RT (Promega). Real time PCR
was performed in the 7500 Fast Real-Time PCR System
(Applied Biosystems) using power SYBR Green PCR
Master Mix (Applied Biosystems). The comparative
threshold cycle method (ΔΔCt) was used to quantify
relative amounts of product transcripts with GAPDH or
18S rRNA (for mRNAs) and hsa-miR-17-5p or U6
snRNA (for miRNAs) as endogenous reference controls.
Primer sets are listed in Additional file 9. Fold activation
values were calculated as mean of three independent
experiments.
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Whole cell lysates having equal protein concentrations
were resolved by SDS/PAGE (6%–12% gel) and trans-
ferred onto a PVDF membrane (Millipore, Billerica,
USA). Various primary antibodies used are goat poly-
clonal NUP214, rabbit polyclonal p-H3, rabbit polyclonal
cyclinA, goat monoclonal Bub1, rabbit polyclonal Nup98
(Santa Cruz Biotechnology, CA, USA), mouse monoclo-
nal cyclinB1 (Cell Signaling Technology, Beverly, MA,
USA) and mouse monoclonal β-actin antibody (Sigma).
Bands were detected using Super Signal West Pico
chemiluminescent substrate (Thermo Scientific, Rockford,
IL, USA) after treating with HRP-conjugated secondary
antibody (Sigma).
Luciferase assay
Cells were lysed with luciferase cell culture lysis reagent
supplied with the luciferase assay kit (Promega). Follow-
ing a short vortex, whole cell lysates were centrifuged at
4°C at 13,000 rpm for 2 min and 15–30 μl of superna-
tants was mixed with 30–60 μl of luciferase assay sub-
strate. Luminescence was measured as relative luciferase
unit (RLU) in GLOMAX luminometer (Promega). Total
protein concentration in each lysate was measured by
Bio-Rad protein assay reagent (Bio-Rad Laboratories,
CA, USA) and then used to normalize the luciferase ac-
tivity of each lysate. Fold activation values were calcu-
lated as mean of three independent experiments.
Cell cycle and apoptotic assays
UPCI:SCC084 cells were synchronized and after release,
approximately 106 cells were harvested at respective
time-points and resuspended in 0.25 ml of cold phos-
phate buffered saline (PBS). Cells were fixed by adding
cold 70% ethanol dropwise into the samples while vor-
texing gently and then incubated at 4°C for minimum
24 h. After fixation, cells were resuspended in 1 ml PBS
containing 100 μg/ml PI (Sigma) and 20 μg/ml RNase A
(Invitrogen). Fixed cells were kept at room temperature
for 40 min and then analysed by FACS (BD FACSARIA™
III, Becton-Dickinson, San Jose, CA, USA).
For annexin V-PI binding assay, UPCI:SCC084 or
HEK293 cells were seeded at a density of 105 cells and
transfected as mentioned. Apoptosis was measured at
the indicated time-points using FITC AnnexinV Apop-
tosis Detection Kit I (BD Pharmingen) according to the
manufacturer’s protocol. Analysis was done by LSRFor-
tesa (Becton-Dickinson).
To measure caspase3/PARP cleavage, 105 UPCI:SCC084
cells were seeded and transiently transfected as men-
tioned. At indicated time-points, cells were fixed with
4% paraformaldehyde, permeabilized by fluorescence-
activated cell sorter permeabilizing solution (BD Biosci-
ences, San Jose, CA, USA). Before staining, permeabilizedcells were treated with heat-inactivated 2% normal goat
serum to block non-specific staining. Cells were then
stained with normal rabbit sera or rabbit anti-human
cleaved caspase3/PARP antibody (Cell Signaling Technol-
ogy). After washing, cells were incubated with multiple
adsorbed FITC-conjugated secondary antibody (goat anti-
rabbit immunoglobulin; BD Biosciences), washed and ana-
lysed by LSRFortesa (Becton-Dickinson).
For colony formation assay, 103 UPCI:SCC084 or
HEK293 cells were seeded and transiently transfected
with indicated concentrations of plasmid. After 7 days,
cells were stained with 0.2% Methylene Blue [Sisco Re-
search laboratories (SRL), Mumbai, India] and washed
with distilled water. The colonies were then counted and
the number of colonies was calculated as mean of three
independent experiments.Immuno-fluorescence
Synchronized HCT116 cells were harvested at different
time-points (as mentioned) after thymidine release. They
were then fixed with ice-cold acetomethanol (1:1) and
permeabilized with 0.03% saponin (Calbiochem, Darmstadt,
Germany). After blocking in 3% BSA, rabbit polyclonal
antibody against p-H3 (Santa Cruz Biotechnology) was
added. Secondary antibody conjugated with FITC (Sigma)
was added and the nuclei were stained with (DAPI) (Invi-
trogen). Slides were observed under a fluorescence
microscope (Leica DM 3000, IL, USA). Abnormal chro-
mosomes were counted among 100–200 cells each time
from three independent experiments and plotted as per-
cent abnormality.Live cell microscopy
HeLa-H4-pEGFP cells were grown in 35 mm dishes with
glass bottoms, transiently transfected (as mentioned)
and synchronized. DMEM medium was replaced with
phenol red-free DMEM medium (Invitrogen). Cells were
monitored for duration in mitosis starting from 8 h post
thymidine release under an inverted fluorescent micro-
scope with live cell chamber (Leica DMI6000) at 37°C
and 5% CO2. Images with a z step size of 500 nm were
captured after every 10 minutes with both DIC and
green channels using a 63× oil immersion objective.Tumour samples
Matched oral tumour (n = 10) and normal (n = 10) tissues
were obtained from the hospital section, Chittaranjan Na-
tional Cancer Institute (CNCI), Kolkata, India. Prior to
sample collection, written informed consent was taken
from each individual and approved by the Research Ethics
Committee of CNCI. The pathological history of the tu-
mours is provided in Additional file 4.
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Target prediction of miR-133b was done by miRBase
(version 17). Complementarity between NUP214-3′UTR
and the seed sequence of miR-133b was obtained from
RNAhybrid (version 2.1) [36] (http://bibiserv.techfak.uni-
bielefeld.de/rnahybrid/). Oncomine 4.4 research edition
database [37] (http://www.oncomine.org/resource/login.
html) was used for the dataset of Nup214 over-expression
in primary tumours. Cancer versus normal datasets of
Nup214 over-expression with fold change ≥1.5 and
p-value ≤0.05 were selected. Densitometric scanning for
Western blots was done by ImageJ software (http://rsb.
info.nih.gov/ij/index.html). Students t test was used to de-
termine statistically significant differences which were de-
fined by 2-sided p < 0.05. GraphPad Prism 5 was used to
perform Mann Whitney t-test in order to determine sig-
nificant differences in miR-133b and NUP214 expressions
between individual groups (normal and tumour).Additional files
Additional file 1: NUP214 is a putative target of miR-133b. (A) The
nucleotide position 9-36 of NUP214 3′ UTR is the recognition site for
miR-133b as predicted by RNAhybrid. Letters in upper case denote the
seed region. (B) The predicted stable RNA-RNA duplex formed by the
binding of human miR-133b to the 3′UTR of NUP214 as given by RNAhybrid.
The RNA strand in green represents miR-133b and the RNA strand in red
represents position 9-36 of NUP214 3′UTR. mfe – minimum free energy.
(C) Nup214 expression is upregulated in different cancers. Expression data
of Nup214 in 23 different cancers from Oncomine database were analyzed.
Cancer versus normal datasets of Nup214 over-expression with fold
change ≥1.5 and p-value ≤0.05 were selected. Bars represent fold over-
expression of Nup214 in these cancers. Electronic supplementary material.
Additional file 2: Analysis of Oncomine dataset shows that Nup214
expression is upregulated in 23 different cancers in comparison to
normal tissues (refer to Additional file 1C). Cancer versus normal
datasets of Nup214 over-expression with fold change ≥1.5 and p-value
≤0.05 were selected.
Additional file 3: Expression values for individual patient samples.
Additional file 4: Pathological details of tumours.
Additional file 5: miR-133b targets NUP214 specifically. (A) Dose-
dependent increase in miR-133b expression upon transient transfection of
UPCI:SCC084 cells with pSB-miR-133b (refer to Figure 1d). (B) ImageJ analysis
of Nup214 bands in Figure 1e normalized to β-actin. (C) Representative picture
showing Nup98 protein level unaffected upon ectopic miR-133b expression.
UPCI:SCC084 cells were transiently transfected with 0 and 1 μg pSB-miR-133b.
Lysates were prepared followed by Western blot with antibodies against
Nup98 and β-actin. (D) BUB1 transcript level is unaffected by ectopic miR-
133b. UPCI:SCC084 cells were transiently transfected with 0, 0.25, 0.5, 1 and 2
μg pSB-miR- 133b. Total RNA isolated was reverse transcribed and cDNA
subjected to RT-PCR using BUB1-specific primers. (E) Representative picture
showing Bub1 protein level unaffected upon ectopic miR-133b expression.
UPCI:SCC084 cells were transiently transfected with 0, 0.25, 0.5, 1 and 2 μg
pSB-miR-133b. Lysates were prepared followed by Western blot with
antibodies against Bub1 and β-actin. (F) ImageJ analysis of Bub1 bands in (E)
normalized to β-actin. (G) NUP214 transcript level remains unaltered in
presence of unrelated miR-125b. UPCI:SCC084 cells were transiently
transfected with 0, 0.25, 0.5 and 1 μg miR-125b expression-plasmid. Total
RNA isolated was reverse transcribed and cDNA subjected to RT-PCR using
NUP214-specific primers. (H) Representative picture showing Nup214 protein
level unaffected upon ectopic expression of miR-125b. UPCI:SCC084 cells
were transiently transfected with 0, 0.25, 0.5 and 1 μg miR-125b expression-plasmid. Lysates were prepared followed by Western blot with antibodies
against Nup214 and β-actin. (I) ImageJ analysis of Nup214 bands in (H)
normalized to β-actin. For (D) and (G), relative expression values were
normalized to those of GAPDH. For (A), (B), (D), (F), (G) and (I), data represent
three independent experiments and are shown as average ± S.D. For (C), (E),
(F) and (H), images are representative of three independent experiments.
Additional file 6: miR-133b-mediated Nup214 repression lengthens
mitotic duration. (A), (B) and (C) HeLa-H4-pEGFP stable cells were
transiently transfected with empty vector (1 μg), pSB-miR-133b (1 μg), or
pSB-miR-133b (1 μg) and pCMV-Myc- CAN/Nup214 (1 μg) and synchronized.
Medium was replaced with phenol red-free medium and visualized under
time lapse fluorescence microscope.
Additional file 7: Excess miR-133b does not modulate cell fate of
non-tumoral cells. (A) and (B) Ectopic miR-133b does not influence
clonogenicity of non-tumoral cells. HEK293 cells were seeded at a density
of 103 and transiently transfected with 0 and 1 μg of pSB-miR-133b.
Colonies were stained with methylene blue after a week. Representative
images are shown (A); colonies were counted from (A) and plotted as
shown (B). (C) and (D) Excess miR-133b does not induce apoptosis in
non-tumoral cells. 105 HEK293 cells were transiently transfected with 0
and 1 μg of pSB-miR-133b. At 72 h post-transfection, cells were subjected
to annexin V-FITC/PI staining followed by flow cytometry analysis and
plotted. For (A) and (C), images are representative of three independent
experiments; for (B), data is shown as average ± S.D.
Additional file 8: Primers used for cloning.
Additional file 9: Primers used for RT-PCR.
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